Successful use of biotherapy with somatostatin analogues in the treatment of a patient with multiple endocrine neoplasia type 1

The syndrome of multiple endocrine neoplasia type I, MEN-1, or Wermer’s syndrome, occupies a separate place in the group neuroendocrine tumors. Being genetic, family-determined disease and having transmission rate 50%, it is manifested by neoplasms various malignant potential many organs. Given trend towards personalization treatment, specialists fields are constantly looking for improved diagnostics new methods treatment. We present our own experience treatment MEN-1 with somatostatin analogues. patient, born 1972, was observed an endocrinologist at age 22, when pituitary microadenoma detected. After 18 years, pancreatic tumor detected, which successfully removed. Histological immunohistochemical studies verified Grade 1 tumor. Control computed tomography revealed masses head tail pancreas. condition, patients since 2013 have been prescribed biotherapy analogue – octreotide. However, taking drug not regular, patient noted deterioration her condition. In 2019, decision council, Lanreotide prescribed. Even into account irregular examinations due to absenteeism, control examination 2022 showed normalization levels chromogranin A serotonin, absence foci progression those during Positron emission tomography. Thus, multidisciplinary approach appointment adequate therapy helps improve quality life stabilize syndrome.